{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-002266","form_type":"8-K","ticker":null,"cik":"0000896747","company_name":"AMERICAN BIO MEDICA CORP","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.470392+00:00","generated_at":"2026-06-18T19:39:23.323573+00:00","sec_items":["2.01","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"American Bio Medica completes sale of substantially all assets for $3M; CEO departs","bullets":["Sale closed Feb 28, 2023; purchase price $3M, with $300K held back for indemnification claims.","Net proceeds to company $247K after paying $965K loan, $1.031M mortgage, $252K unsecured loan, and $205K taxes.","CEO Melissa Waterhouse employment terminated March 1; she will consult up to 3 months for $4K/month retainer, payment suspended.","Waterhouse deferred $92K salary and $29K current salary until ERC refund of $202K or retention fund release.","Company now seeks new line of business or business combination using publicly traded stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-002266","json":"https://secwatch.observer/filing/0001654954-23-002266.json","markdown":"https://secwatch.observer/filing/0001654954-23-002266.md","text":"https://secwatch.observer/filing/0001654954-23-002266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/abmc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T19:39:23.323573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1525f62583","claim":"Melissa A. Waterhouse was terminated as Chief Executive Officer at AMERICAN BIO MEDICA CORP.","evidence_excerpt":"the employment agreement with the Company’s Chief Executive Officer/ Principal Financial Officer, Melissa Waterhouse, was terminated effective March 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c9dcaf1c00b28b54a1ccddfbaa361d3b3f79f039","claim":"AMERICAN BIO MEDICA CORP completed a disposition involving Healgen Scientific Limited Liability Company for $3 million (closed 2023-02-28).","evidence_excerpt":"the Company’s assets. In connection with the closing of the Sale, and in accordance with the terms of the Asset Purchase Agreement, the Buyer paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Healgen Scientific Limited Liability Company"},{"label":"Consideration","value":"$3 million"},{"label":"Closing","value":"2023-02-28"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}